Aurinia Pharmaceuticals Inc. (AUPH): Cash & Equivalents
$80.16M
As of 2025-12-31
$179.73M
As of 2026-06-30
-5.2%
3-year compound annual growth
-21.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $80.16M | -3.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $83.40M | +71.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $48.76M | -48.2% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $94.09M | -59.4% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $231.64M | -14.9% | 2024-02-15, Balance as of period end |
| 2020-12-31 | $272.35M | -11.0% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $306.02M | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $80.16M | -3.9% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $225.27M | +114.8% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $354.73M | +282.9% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $85.72M | -4.1% |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗